Bioethics: Early Access to Experimental Products Programs: Points to Consider

  • Recommend
  • Tweet
  • Print
  • Email
Teaser: 

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Read the document (183 KB PDF) [2]

Hide Related Contenet: 
Show
Hide Date: 
Show
Show Author Info?: 
Show Author Info?